Submission from Allergy & Anaphylaxis Australia (A&AA):Dupixent for severe eczema. 

A&AA asks that you consider the changed lives of people with severe eczema who are now taking Dupixent in the July 2022 PBAC meeting.

People are utilising the medication because there has been a huge need for a treatment that works without the need for immunosuppressive medication.

People are sharing their stories and those who were disengaged are now re engaging with health professionals that can review their health condition and offer those with severe eczema this new treatment

Submission concerning Dupixent for severe eczema - 16 May 2022177.41 KB